Clinica Vitae Sp. z o.o.

Gdansk 9 trials 2 recruiting

9 Registered trials

2 Currently recruiting

Organisation

Clinica Vitae Sp. z o.o.

Location

Gdansk, Poland

Identifier

ORG-100046002

Address

Ul. Gospody 7, 80-344, Poland

Departments

Clinica Vitae Sp. z o.o.
Department of pulmonology and allergology
N/A
NA
Przychodnia Clinica Vitae (#1)
Przychodnia pulmonologii I alergologii

Clinical trials at this site (9)

Search interface

A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting

2025-523180-38-00 Uncontrolled Moderate to Severe Eosinophilic Asthma 4 2026-05-21
Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting

2023-508520-36-00 Seasonal allergic rhinitis/rhinoconjunctivitis induced 5 2024-09-06
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea… Ended

2023-503385-24-00 Asthma 4 2024-03-12
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended

2024-514764-72-00 Chronic Urticaria 5 2023-09-27
A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o… Ended

2023-509833-38-00 Birch Pollen-induced Allergic Rhinoconjunctivitis 5 2023-09-20
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended

2024-510641-33-00 Asthma 4 2023-01-17